About Us

Publications

BMT CTN investigators have published >135 manuscripts, including >30 primary study results papers, in numerous peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Blood. Selected publications are summarized for dissemination to patients and the lay public.

Note: Some Publications were unable to be listed below - please see that listing here. All other publications based on PubMedIDs are listed below.

 

Found 66 results
Filters: Keyword is Middle Aged  [Clear All Filters]
2022
L. Luznik, Pasquini, M. C., Logan, B., Soiffer, R. J., Wu, J., Devine, S. M., Geller, N., Giralt, S., Heslop, H. E., Horowitz, M. M., Jones, R. J., Litzow, M. R., Mendizabal, A., Muffly, L., Nemecek, E. R., O'Donnell, L., O'Reilly, R. J., Palencia, R., Schetelig, J., Shune, L., Solomon, S. R., Vasu, S., Ho, V. T., and Perales, M. - A., “Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies.”, J Clin Oncol, vol. 40, no. 4, pp. 356-368, 2022.
2021
R. Reshef, Saber, W., Bolaños-Meade, J., Chen, G., Bin Chen, Y. -, Ho, V. T., Ponce, D. M., Nakamura, R., Martens, M. J., Hansen, J. A., and Levine, J. E., “Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study.”, J Clin Oncol, vol. 39, no. 17, pp. 1878-1887, 2021.
R. Nakamura, Saber, W., Martens, M. J., Ramirez, A., Scott, B., Oran, B., Leifer, E., Tamari, R., Mishra, A., Maziarz, R. T., McGuirk, J., Westervelt, P., Vasu, S., Patnaik, M., Kamble, R., Forman, S. J., Sekeres, M. A., Appelbaum, F., Mendizabal, A., Logan, B., Horowitz, M., and Cutler, C., “Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.”, J Clin Oncol, vol. 39, no. 30, pp. 3328-3339, 2021.
E. J. Fuchs, O'Donnell, P. V., Eapen, M., Logan, B., Antin, J. H., Dawson, P., Devine, S., Horowitz, M. M., Horwitz, M. E., Karanes, C., Leifer, E., Magenau, J. M., McGuirk, J. P., Morris, L. E., Rezvani, A. R., Jones, R. J., and Brunstein, C. G., “Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial.”, Blood, vol. 137, no. 3, pp. 420-428, 2021.
B. L. Scott, Pasquini, M. C., Fei, M., Fraser, R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E., Fernandez, H. F., Soiffer, R. J., Alyea, E., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Hourigan, C. S., Gui, G., Mendizabal, A., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.”, Transplant Cell Ther, vol. 27, no. 6, pp. 483.e1-483.e6, 2021.
2020
C. S. Hourigan, Dillon, L. W., Gui, G., Logan, B. R., Fei, M., Ghannam, J., Li, Y., Licon, A., Alyea, E. P., Bashey, A., H Deeg, J., Devine, S. M., Fernandez, H. F., Giralt, S., Hamadani, M., Howard, A., Maziarz, R. T., Porter, D. L., Scott, B. L., Warlick, E. D., Pasquini, M. C., and Horwitz, M. E., “Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.”, J Clin Oncol, vol. 38, no. 12, pp. 1273-1283, 2020.
J. Pidala, Hamadani, M., Dawson, P., Martens, M., Alousi, A. M., Jagasia, M., Efebera, Y. A., Chhabra, S., Pusic, I., Holtan, S. G., Ferrara, J. L. M., Levine, J. E., Mielcarek, M., Anasetti, C., Antin, J. H., Bolaños-Meade, J., Howard, A., Logan, B. R., Leifer, E. S., Pritchard, T. S., Horowitz, M. M., and MacMillan, M. L., “Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial.”, Blood, vol. 135, no. 2, pp. 97-107, 2020.
2019
R. F. Ambinder, Wu, J., Logan, B., Durand, C. M., Shields, R., Popat, U. R., Little, R. F., McMahon, D. K., Cyktor, J., Mellors, J. W., Ayala, E., Kaplan, L. D., Noy, A., Jones, R. J., Howard, A., Forman, S. J., Porter, D., Arce-Lara, C., Shaughnessy, P., Sproat, L., Hashmi, S. K., Mendizabal, A. M., Horowitz, M. M., Navarro, W. H., and Alvarnas, J. C., “Allogeneic Hematopoietic Cell Transplant for HIV Patients with Hematologic Malignancies: The BMT CTN-0903/AMC-080 Trial.”, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2160-2166, 2019.
A. Rashidi, Shanley, R., Anasetti, C., Waller, E. K., Scott, B. L., Blazar, B. R., and Weisdorf, D. J., “Analysis of BMT CTN-0201 and -0901 samples did not reproduce the reported association between recipient REG3A rs7588571 and chronic GVHD.”, Bone Marrow Transplant, vol. 54, no. 3, pp. 490-493, 2019.
A. Rashidi, Luo, X., Cooley, S., Anasetti, C., Waller, E. K., Brunstein, C. G., Cichocki, F., Weisdorf, D. J., and Miller, J. S., “The association of CMV with NK-cell reconstitution depends on graft source: results from BMT CTN-0201 samples.”, Blood Adv, vol. 3, no. 16, pp. 2465-2469, 2019.
E. A. Stadtmauer, Pasquini, M. C., Blackwell, B., Hari, P., Bashey, A., Devine, S., Efebera, Y., Ganguly, S., Gasparetto, C., Geller, N., Horowitz, M. M., Koreth, J., Knust, K., Landau, H., Brunstein, C., McCarthy, P., Nelson, C., Qazilbash, M. H., Shah, N., Vesole, D. H., Vij, R., Vogl, D. T., Giralt, S., Somlo, G., and Krishnan, A., “Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial.”, J Clin Oncol, vol. 37, no. 7, pp. 589-597, 2019.
J. Paul, Nakasone, H., Sahaf, B., Wu, F., Wang, K., Ho, V., Wu, J., Kim, H., Blazar, B., Ritz, J., Howard, A., Cutler, C., and Miklos, D., “A confirmation of chronic graft--host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation.”, Haematologica, vol. 104, no. 7, pp. e314-e317, 2019.
M. Gooptu, Kim, H. T., Howard, A., Choi, S. W., Soiffer, R. J., Antin, J. H., Ritz, J., and Cutler, C. S., “Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clini”, Biol Blood Marrow Transplant, vol. 25, no. 11, pp. 2143-2151, 2019.
J. Bolaños-Meade, Reshef, R., Fraser, R., Fei, M., Abhyankar, S., Al-Kadhimi, Z., Alousi, A. M., Antin, J. H., Arai, S., Bickett, K., Bin Chen, Y. -, Damon, L. E., Efebera, Y. A., Geller, N. L., Giralt, S. A., Hari, P., Holtan, S. G., Horowitz, M. M., Jacobsohn, D. A., Jones, R. J., Liesveld, J. L., Logan, B. R., MacMillan, M. L., Mielcarek, M., Noel, P., Pidala, J., Porter, D. L., Pusic, I., Sobecks, R., Solomon, S. R., Weisdorf, D. J., Wu, J., Pasquini, M. C., and Koreth, J., “Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with ”, Lancet Haematol, vol. 6, no. 3, pp. e132-e143, 2019.
2018
S. G. Holtan, DeFor, T. E., Panoskaltsis-Mortari, A., Khera, N., Levine, J. E., Flowers, M. E. D., Lee, S. J., Inamoto, Y., Chen, G. L., Mayer, S., Arora, M., Palmer, J., Cutler, C. S., Arai, S., Lazaryan, A., Newell, L. F., Jagasia, M. H., Pusic, I., Wood, W. A., Renteria, A. S., Yanik, G., Hogan, W. J., Hexner, E., Ayuk, F., Holler, E., Bunworasate, U., Efebera, Y. A., Ferrara, J. L. M., Pidala, J., Howard, A., Wu, J., Bolaños-Meade, J., Ho, V., Alousi, A., Blazar, B. R., Weisdorf, D. J., and MacMillan, M. L., “Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802.”, Blood Adv, vol. 2, no. 15, pp. 1882-1888, 2018.
M. C. Pasquini, Logan, B., Jones, R. J., Alousi, A. M., Appelbaum, F. R., Bolaños-Meade, J., Flowers, M. E. D., Giralt, S., Horowitz, M. M., Jacobsohn, D., Koreth, J., Levine, J. E., Luznik, L., Maziarz, R., Mendizabal, A., Pavletic, S., Perales, M. - A., Porter, D., Reshef, R., Weisdorf, D., and Antin, J. H., “Blood and Marrow Transplant Clinical Trials Network Report on the Development of Novel Endpoints and Selection of Promising Approaches for Graft-versus-Host Disease Prevention Trials.”, Biol Blood Marrow Transplant, vol. 24, no. 6, pp. 1274-1280, 2018.
L. M. Turcotte, DeFor, T. E., Newell, L. F., Cutler, C. S., Verneris, M. R., Wu, J., Howard, A., MacMillan, M. L., Antin, J. H., Vercellotti, G. M., Slungaard, A., Blazar, B. R., Weisdorf, D. J., Panoskaltsis-Mortari, A., and Holtan, S. G., “Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.”, Bone Marrow Transplant, vol. 53, no. 1, pp. 64-68, 2018.
R. Spellecy, Tarima, S., Denzen, E., Moore, H., Abhyankar, S., Dawson, P., Foley, A., Gersten, I., Horwitz, M., Idossa, L., Joffe, S., Kamani, N., King, R., Lazaryan, A., Morris, L., Horowitz, M. M., and Majhail, N. S., “Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study.”, Biol Blood Marrow Transplant, vol. 24, no. 10, pp. 2145-2151, 2018.
P. A. Carpenter, Logan, B. R., Lee, S. J., Weisdorf, D. J., Johnston, L., Costa, L. J., Kitko, C. L., Bolaños-Meade, J., Sarantopoulos, S., Alousi, A. M., Abhyankar, S., Waller, E. K., Mendizabal, A., Zhu, J., O'Brien, K. A., Lazaryan, A., Wu, J., Nemecek, E. R., Pavletic, S. Z., Cutler, C. S., Horowitz, M. M., and Arora, M., “A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801.”, Haematologica, vol. 103, no. 11, pp. 1915-1924, 2018.
H. S. L. Jim, Sutton, S., Majhail, N. S., Wood, W. A., Jacobsen, P. B., Wingard, J. R., Wu, J., Knight, J. M., Syrjala, K. L., and Lee, S. J., “Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial.”, Bone Marrow Transplant, vol. 53, no. 8, pp. 1038-1043, 2018.
E. P. Smith, Li, H., Friedberg, J. W., Constine, L. S., Rimsza, L. M., Cook, J. R., Laport, G. G., Popplewell, L. L., Holmberg, L. A., Smith, S. M., LeBlanc, M., Forman, S. J., Fisher, R. I., and Stiff, P. J., “Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703).”, Biol Blood Marrow Transplant, vol. 24, no. 4, pp. 700-707, 2018.
2017
K. L. Syrjala, Sutton, S. K., Jim, H. S. L., Knight, J. M., Wood, W. A., Lee, S. J., Jacobsen, P. B., Abidi, M. H., and Yi, J. C., “Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis.”, Cancer, vol. 123, no. 8, pp. 1416-1423, 2017.
S. G. Holtan, Newell, L. F., Cutler, C., Verneris, M. R., DeFor, T. E., Wu, J., Howard, A., MacMillan, M. L., Antin, J. H., Blazar, B. R., Weisdorf, D. J., and Panoskaltsis-Mortari, A., “Low EGF in myeloablative allotransplantation: association with severe acute GvHD in BMT CTN 0402.”, Bone Marrow Transplant, vol. 52, no. 9, pp. 1300-1303, 2017.
B. L. Scott, Pasquini, M. C., Logan, B. R., Wu, J., Devine, S. M., Porter, D. L., Maziarz, R. T., Warlick, E. D., Fernandez, H. F., Alyea, E. P., Hamadani, M., Bashey, A., Giralt, S., Geller, N. L., Leifer, E., Le-Rademacher, J., Mendizabal, A. M., Horowitz, M. M., H Deeg, J., and Horwitz, M. E., “Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.”, J Clin Oncol, vol. 35, no. 11, pp. 1154-1161, 2017.
M. Arora, Weisdorf, D. J., Shanley, R. M., and Thyagarajan, B., “Pharmacogenetics of steroid-responsive acute graft-versus-host disease.”, Clin Transplant, vol. 31, no. 5, 2017.